How to Increase Rexulti (Brexpiprazole) Dose
Start Rexulti at 0.5-1 mg once daily and titrate gradually over 1-2 weeks to reach the target therapeutic dose of 2-4 mg/day, with the specific titration schedule depending on the indication being treated.
Titration Schedule by Indication
For Schizophrenia (Adults)
The FDA-approved titration is straightforward: 1
- Days 1-4: Start at 1 mg once daily
- Days 5-7: Increase to 2 mg once daily
- Day 8 onward: Either maintain at 2 mg or increase to 4 mg once daily based on clinical response
- Target dose range: 2-4 mg/day
This represents a relatively rapid titration over just one week to reach therapeutic dosing.
For Schizophrenia (Adolescents 13-17 years)
A more gradual approach is used in younger patients: 1
- Days 1-4: 0.5 mg once daily
- Days 5-7: 1 mg once daily
- Days 8-14: 2 mg once daily
- Days 15-21: Either maintain at 2 mg or increase to 3 mg once daily
- After Day 21: Can adjust by 1 mg increments up to maximum 4 mg daily based on tolerability and response
For Major Depressive Disorder (Adjunctive Treatment)
The slowest titration schedule is used for depression: 1
- Week 1: 0.5 mg once daily
- Week 2: Increase to 1 mg once daily
- Week 3 onward: Increase to target dose of 2 mg once daily (can go up to 3 mg if needed)
- Target dose range: 2-3 mg/day (2 mg is recommended)
For Agitation in Alzheimer's Dementia
Two different titration approaches were studied: 1
- Slower approach: 0.25 mg daily × 3 days → 0.5 mg daily × 12 days → 1 mg daily × 14 days → target dose (1-2 mg)
- Faster approach: 0.5 mg daily × 7 days → 1 mg daily × 7 days → 2 mg daily × 14 days → target dose (2-3 mg)
Key Clinical Considerations
Why Gradual Titration Matters
The gradual dose escalation serves several purposes:
- Minimizes akathisia risk: While akathisia rates are relatively low (5.5% vs 4.6% placebo in schizophrenia trials), slow titration helps prevent this dose-dependent side effect 2, 3
- Reduces initial sedation: Somnolence is common early in treatment (10.2% in adolescents) 4
- Allows monitoring for weight gain: Approximately 10-20% of patients experience clinically significant weight gain (≥7% from baseline), which should be monitored throughout titration 2, 4
Common Pitfalls to Avoid
Do not rush the titration. Unlike some antipsychotics, brexpiprazole requires patience—it can take 6-12 weeks to separate from placebo in agitation trials 5. Premature dose escalation increases side effect burden without accelerating therapeutic benefit.
Do not exceed 4 mg/day. Higher doses have not demonstrated superior efficacy and may increase adverse effects. In schizophrenia trials, both 2 mg and 4 mg doses showed efficacy, with the 4 mg dose not consistently outperforming 2 mg 1.
Dose Adjustments for Drug Interactions
Reduce dose by 50% when co-administered with strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine) or strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin).
Reduce dose by 75% when both a strong CYP2D6 AND strong CYP3A4 inhibitor are used concurrently.
Double the usual dose when used with strong CYP3A4 inducers (e.g., rifampin, carbamazepine).
Monitoring During Titration
Track these parameters as you increase the dose:
- Weight and BMI at each visit (especially critical in adolescents where 19.8% experienced clinically meaningful weight gain) 4
- Movement disorders (akathisia, extrapyramidal symptoms)
- Sedation/somnolence particularly in the first 2-4 weeks
- Metabolic parameters (glucose, lipids) at baseline and periodically, though effects are generally modest 2, 3
When to Stop Titrating
Reach the minimum effective dose that controls symptoms. In schizophrenia, 2 mg may be sufficient for many patients (NNT=7 for response) 3. For MDD adjunctive treatment, 2 mg is the recommended target dose 1. Only increase to higher doses if inadequate response after adequate trial duration at lower doses.